The S&P 500 had a good week due to the impressive start of Q1 earnings and favorable inflation data. In March, the consumer price index rose 5%, lower than the previous month's 6%, and met economists' expectations.
Pfizer: a controversial outlook
2021-02-01 • Updated
Pfizer reports its Q4’2020 performance on Tuesday, at 17:00 MT time.
Its EPS is expected to be within the range of $0.45-0.50. Will Pfizer manage to beat the forecast? There are mixed reviews on that. In Q4, Pfizer completed the separation of the Upjohn unit to form “New Pfizer”. Sales of its primary medications have been pretty good during the months September-December. However, some particular products have declined. In addition, the disruption of doctor visits and related healthy activities around the world may have brought significant damage as well. That’s why observers are very moderate with optimism on Pfizer. The same controversy appears when you look at the chart.
The long-term view doesn’t suggest any firm uptrend. Rather, a continuous oscillation and mid-term friction. While the 2007-2018 performance has been a steady uptrend that ended at the highs above $43, the recent years did favor this stock too much. It met the Covid-19 era at the lows of $28. Thanks to the vaccine, it rose to $43 – the entrance to the highest-ever area where it was in 2018 and 2002. However, the vaccine rush seems to have cooled off, and the stock price doesn’t seem to be in an uptrend.
Therefore, in the scenario of weak performance, bears will likely drag it below $35, and the nearest mid-term will likely see it between $32 and $35.
Otherwise, if Pfizer manages to give a positive surprise to investors against the expected EPS of $0.45, the stock may reverse to the upside and get pushed to approach $43 again.
Don't know how to trade stocks? Here are some simple steps.
- First of all, be sure you’ve downloaded Metatrader 5 or FBS Trader app. FBS allows you to trade stocks only through this software.
- Open the MT5 account in your personal area (in account in FBS Trader)
- Start trading!
The previous year 2022, was undoubtedly tumultuous for the stock markets, with several stocks plummeting across multiple industries. Analysts have blamed the hard times on inflation, hawkish federal reserve policies, an impending global recession, and the ongoing crisis in Ukraine. This year, however, we're beginning to see some recovery in the stock markets. This article will find a few stocks worth buying this year.
In a call scheduled for January 25, 00:30 am GMT+2, Microsoft will publish the company's earnings for the final quarter of 2022 and comment on the results, projections, and outlook for the nearest future of the company.
Let's dive into the world of gold. Currently, the price of gold, represented by XAUUSD, is stuck in indecision, hovering around the $1,975 mark. The market is anxiously awaiting two important factors: the release of the Federal Reserve's meeting minutes and the extension of the US debt ceiling.
Hey guys, this is the last full trading week in May, and many forward-looking individuals like myself are already preparing themselves to seize whatever opportunities June may have in store. On this note, I will review a few commodities that have satisfied my quest for swing-trading opportunities in the coming month. Follow me!
The Bank of England (BoE) has dramatically shifted its economic forecasts. They no longer expect a recession in the UK and have upgraded their growth projections. This year, the BoE predicts GDP growth of +0.25%, a significant improvement from previous expectations. Next year's forecast is even more optimistic, with a projected growth of 0.75%.